. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: J Am Med Dir Assoc. 2016 Jun 24;17(9):852–859. doi: 10.1016/j.jamda.2016.05.011

Table 4.

Pharmacological Prevention of Fractures in RACF Residents Versus Community-Dwelling Older Persons

Agent	Dose	Evidence in Institutionalized Older Persons	Hip Fracture (RRR) General Population
Cholecalciferol	800–1000 IU/day	Yes (Fx prevention) (level I)	0.12–0.29
Alendronate	70 mg/weekly	Yes (only BMD) (level II)	0.45–0.51
Risedronate	35 mg/weekly	No	0.30–0.40
Zoledronate	5 mg/annually	No	0.41
Denosumab	60 mg/6 mo	No	0.40 (0.60 in older)
Teriparatide	40 μg/day	No	0.25

BMD, bone mineral density; Fx, fracture; RACF, residential aged care facility; RRR, relative risk reduction.